Kaya

Kaya Debt/EBITDA

The Total Debt to EBITDA Ratio of Kaya (KAYA.NS) as of Nov 4, 2026 is -4.88. In the previous year, Total Debt to EBITDA Ratio was 7.34 — a change of -166.50% (lower).

Debt/EBITDA

-4.88

YoY

-166.50%

Last updated:

Total Debt to EBITDA Ratio of Kaya is 2026 -4.88 . Total Debt to EBITDA Ratio of Kaya was 2025 7.34 . It decreases by -166.50% lower compared to the previous year.

The Kaya Debt/EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt/EBITDA
Date
Debt/EBITDA
Jan 1, 2019
3.28 INR
Jan 1, 2020
2.65 INR
Jan 1, 2021
4.27 INR
Jan 1, 2022
20.02 INR
Jan 1, 2023
17.70 INR
Jan 1, 2024
9.69 INR
Jan 1, 2025
7.34 INR
Jan 1, 2026
-4.88 INR
The Kaya Debt/EBITDA history
YEARDebt/EBITDAYoY
-4.88-166.50%
7.34-24.23%
9.69-45.25%
17.70-11.60%
20.02+368.78%
4.27+60.90%
2.65-19.00%
3.28-68.12%
10.28+429.83%
1.94+16,974.48%
0.01-37.15%
0.02-99.79%
8.80—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Kaya Stock analysis

What does Kaya do? Kaya Ltd. generates revenue through its portfolio of health care aesthetics, beauty, and personal care products and services. The company develops specialty products and services in collaboration with its dermatologists, offering solutions for acne, pigmentation, dull skin, and hair concerns. Its product range includes over 80 items such as acne treatments, brightening serums, anti-ageing creams, derma naturals, body care, hair care, and beauty facials. The firm targets consumers seeking professional skin and hair care, particularly those addressing everyday skin and hair needs through its dermatologist-developed offerings. Kaya Ltd. provides a variety of skin and hair-based services, including Oxygeneo Medifacial, Skin and Eye Threads, Profhilo Fillers, Restylane Lyft, Restylane Kysse, and High-intensity focused ultrasound. These services cater to clients looking for advanced aesthetic treatments. The company also offers body care solutions like CoolSculpting Technology, Enzymatic Resurfacing, Venus Legacy, and Happy Intim intimate rejuvenation, appealing to customers focused on body contouring and intimate wellness. Additionally, its skin care services such as IV Boost, DNA Repair Therapy, and Skin Boosters Jalupro target clients seeking specialized skin health solutions. The firm’s revenue streams are derived from both product sales and service offerings, with its dermatologist-developed products and services forming the core of its business model. Kaya Ltd. serves a segment of health-conscious consumers who prioritize professional-grade skin and hair care, leveraging its expertise in dermatology to address specific concerns like acne, pigmentation, and hair issues. The company’s focus on specialty treatments ensures repeat business and customer loyalty within its target market. Kaya is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Kaya stock

Total Debt to EBITDA Ratio of Kaya is -4.88 in 2026.

Total Debt to EBITDA Ratio of Kaya changed from 7.34 to -4.88, representing a -166.50% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Total Debt to EBITDA Ratio Kaya since 2006 – with annual values, charts, and detailed analysis.

Debt/EBITDA measures total debt relative to earnings before interest, taxes, depreciation, and amortization. It indicates the years needed to repay all debt from EBITDA.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Total Debt to EBITDA Ratio's Kaya with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Kaya

All Key Metrics — Kaya